(Boursier.com) — The unaudited statutory turnover of Novacyt for FY2023 is expected to be approximately £11.6 million, as forecast, of which £0.6 million is COVID-related (FY2022: £21 million, of which £14.7 million is COVID-related pounds sterling).
The Group’s unaudited statutory turnover for the non-COVID portfolio of £11 million represents over 95% of total turnover (FY2022: £6.3 million).
The cash position at 31 December 2023 was £44.1 million (H1 2023: £81.7 million), reflecting the cash consideration and associated costs of the Yourgene acquisition, and the Group remains free of any debt.
The Group’s Pro-Forma revenue for the 12 months ended 31 December 2023 was £22.9 million (2022: £44.3 million).
Excluding COVID-related sales, core Pro-Forma revenue for the 12 months ended December 2023 was £21.8 million, compared to £22.9 million for the 12 months ended December 2023. 2022, a drop of £1.1 million or around 5%.
©2024 Boursier.com